Jim Simons’s NeuroSense Therapeutics NRSN Stock Holding History

Jim Simons’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-71,100	Closed	-$129K	–	3819
2024 Q1	$129K	Buy	+71,100	New	+$95.7K	﹤0.01%	3322
2023 Q1	–	Sell	-18,433	Closed	-$22K	–	4266
2022 Q4	$22K	Sell	18,433 -35,867	-66%	-$57K	﹤0.01%	3946
2022 Q3	$97K	Buy	+54,300	New	+$111K	﹤0.01%	3606

Other funds holding NRSN

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jim Simons's NRSN Position: Q2 2024 in Review

Jim Simons sold out of NeuroSense Therapeutics (NRSN) in Q2 2024, closing a stake of 71,100 shares — an estimated $129K sold.

Jim Simons first reported a position in NRSN in Q3 2022 and held it in 3 quarters. The position peaked at $129K in Q1 2024. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2024.

Jim Simons reported no remaining NeuroSense Therapeutics position as of Q2 2024 after selling out during the quarter.
Jim Simons sold 71,100 NeuroSense Therapeutics shares in Q2 2024, an estimated $129K.
Jim Simons first reported a position in NeuroSense Therapeutics in Q3 2022 and held it in 3 quarters.
Jim Simons's NeuroSense Therapeutics position peaked at $129K in Q1 2024.
7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.